NCT02540876View on ClinicalTrials.gov

Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 8, 2015

Primary Completion Date

February 8, 2019

Study Completion Date

February 8, 2019

Conditions

Metastatic Malignant NeoplasmSolid NeoplasmUnresectable Malignant Neoplasm

Interventions

DRUG

Ilorasertib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

60637

University of Chicago Comprehensive Cancer Center, Chicago

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Chicago

OTHER

NCT02540876 - Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery | Biotech Hunter | Biotech Hunter